What is the address of PHARMA PROJECT?

The registered office of PHARMA PROJECT is located at Place Cardinal Mercier 6, 1300 Wavre.

Is PHARMA PROJECT still active?

Yes. According to the CBE (31 October 2026) PHARMA PROJECT is active, legal situation “Normale toestand”, started on 19 June 1996.

Is PHARMA PROJECT registered on Peppol?

Yes, PHARMA PROJECT is registered on the Peppol network with ID 0208:0458257001.

What is the enterprise number of PHARMA PROJECT?

The enterprise number of PHARMA PROJECT is BE0458257001.

When was PHARMA PROJECT founded?

PHARMA PROJECT was founded on 19 June 1996.

Who are the directors of PHARMA PROJECT?

According to the 2025 annual accounts, the directors of PHARMA PROJECT are: GILLES SMITS, JEAN-JACQUES SMITS, NICOLE VANSTEENKISTE.

Is PHARMA PROJECT a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 19 June 1996; 4 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did PHARMA PROJECT make in 2025?

PHARMA PROJECT recorded a loss after taxes of € 11,278 in financial year 2025.

What is the revenue of PHARMA PROJECT?

As a small company, PHARMA PROJECT is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 83,959.

PHARMA PROJECT (Public Limited) - Wavre - BE0458257001

Dossier PHARMA PROJECT, printed on 31 October 2026 from databakkes.be/en/0458257001/pharma-project. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 4 of the last 4 fiscal years.
Tight liquidity NBB

Cash and receivables cover 2 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

PHARMA PROJECT from Wavre, company number BE0458257001, closed financial year 2025 with a result of € -11,278 after tax. For that financial year PHARMA PROJECT recorded a gross margin of € 83,959 and equity of € -33,296. Compared with financial year 2024, the result moved from € 1,627 to € -11,278. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on January 5, 2026.

What it is worth Caution

€ -33,296

▼ € 11,278 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -11,278

▼ still € 1,627 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 11,865

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -839,182.

People and assets in 2025

Vehicles and equipment

€ 598,272

▼ 10% vs 2024

Of which on lease € 596,181.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 461,661

▼ 21% vs 2024

€ 102,889 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 9,878

▲ € 8,228 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 1,492

▲ 41% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 94,202 Gross margin 2022: € 94,202 First fiscal year in the series	€ 89,298 Gross margin 2023: € 89,298 ▼ 5% vs 2022 (€ 94,202) Unfavourable step	€ 98,259 Gross margin 2024: € 98,259 ▲ 10% vs 2023 (€ 89,298) Favourable step	€ 83,959 Gross margin 2025: € 83,959 ▼ 15% vs 2024 (€ 98,259) Unfavourable step	▼ 15%
Profit after taxes	€ -11,819 Profit after taxes 2022: € -11,819 First fiscal year in the series	€ -13,986 Profit after taxes 2023: € -13,986 ▼ € 2,167 vs 2022 (€ -11,819) Unfavourable step	€ 1,627 Profit after taxes 2024: € 1,627 ▲ € 15,613 vs 2023 (€ -13,986) Favourable step	€ -11,278 Profit after taxes 2025: € -11,278 ▼ € 12,905 vs 2024 (€ 1,627) Unfavourable step	▼ € 12,905
Equity	€ -9,659 Equity 2022: € -9,659 First fiscal year in the series	€ -23,645 Equity 2023: € -23,645 ▼ € 13,986 vs 2022 (€ -9,659) Unfavourable step	€ -22,018 Equity 2024: € -22,018 ▲ € 1,627 vs 2023 (€ -23,645) Favourable step	€ -33,296 Equity 2025: € -33,296 ▼ € 11,278 vs 2024 (€ -22,018) Unfavourable step	▼ € 11,278
Total debts	€ 1,021,861 Total debts 2022: € 1,021,861 First fiscal year in the series	€ 959,956 Total debts 2023: € 959,956 ▼ 6% vs 2022 (€ 1,021,861) Favourable step	€ 884,976 Total debts 2024: € 884,976 ▼ 8% vs 2023 (€ 959,956) Favourable step	€ 839,308 Total debts 2025: € 839,308 ▼ 5% vs 2024 (€ 884,976) Favourable step	▼ 5%
Cash	€ 4,983 Cash 2022: € 4,983 First fiscal year in the series	€ 3,079 Cash 2023: € 3,079 ▼ 38% vs 2022 (€ 4,983) Unfavourable step	-	€ 11,865 Cash 2025: € 11,865 First fiscal year in the series
Land & buildings	€ 208,073 Land & buildings 2022: € 208,073 First fiscal year in the series	€ 203,213 Land & buildings 2023: € 203,213 ▼ 2% vs 2022 (€ 208,073) Unchanged	€ 198,353 Land & buildings 2024: € 198,353 ▼ 2% vs 2023 (€ 203,213) Unchanged	€ 193,493 Land & buildings 2025: € 193,493 ▼ 2% vs 2024 (€ 198,353) Unchanged	▼ 2%
Retained profit	€ -815,545 Retained profit 2022: € -815,545 First fiscal year in the series	€ -829,531 Retained profit 2023: € -829,531 ▼ € 13,986 vs 2022 (€ -815,545) Unfavourable step	€ -827,904 Retained profit 2024: € -827,904 Unchanged (€ -829,531) Favourable step	€ -839,182 Retained profit 2025: € -839,182 ▼ € 11,278 vs 2024 (€ -827,904) Unfavourable step	▼ € 11,278
Bank debt	€ 762,550 Bank debt 2022: € 762,550 First fiscal year in the series	€ 665,306 Bank debt 2023: € 665,306 ▼ 13% vs 2022 (€ 762,550) Favourable step	€ 585,434 Bank debt 2024: € 585,434 ▼ 12% vs 2023 (€ 665,306) Favourable step	€ 461,661 Bank debt 2025: € 461,661 ▼ 21% vs 2024 (€ 585,434) Favourable step	▼ 21%
Balance sheet total	€ 1,012,202 Balance sheet total 2022: € 1,012,202 First fiscal year in the series	€ 936,311 Balance sheet total 2023: € 936,311 ▼ 7% vs 2022 (€ 1,012,202) Unchanged	€ 862,958 Balance sheet total 2024: € 862,958 ▼ 8% vs 2023 (€ 936,311) Unchanged	€ 806,013 Balance sheet total 2025: € 806,013 ▼ 7% vs 2024 (€ 862,958) Unchanged	▼ 7%

Key figures of PHARMA PROJECT, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.

What happened to PHARMA PROJECT?

What happened at PHARMA PROJECT in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2026 GILLES SMITS stepped down as director. NBB
2026 JEAN-JACQUES SMITS stepped down as director. NBB
2026 NICOLE VANSTEENKISTE stepped down as director. NBB
Jan 5, 2026 New annual accounts for financial year 2025: loss of € 11,278 (▼ € 12,905 vs 2024). Source: NBB ↗
2020 GILLES SMITS became a director. NBB
2020 JEAN-JACQUES SMITS became a director. NBB
2020 NICOLE VANSTEENKISTE became a director. NBB
Dec 12, 1996 New establishment in Wavre. KBO

In short

From € 11,819 loss in 2022 to € 11,278 loss in 2025.

Best year ever: 2024, with € 1,627 profit.

Original PDFs at the National Bank ↗

Management

Directors

According to the 2025 annual accounts

GILLES SMITS

Director

Also active at: Wavrienne de Gestion Immobilière, HG IMMO, HG Pharma, Pharmacie Smits Basse Wavre, PHARMACIE SMITS

since 2020 · until 2026

JEAN-JACQUES SMITS

Managing director

Also active at: PLANT SUN, PHARMACIE SMITS ECHT, Pharma Project II, PHARMACIE SMITS ZONING NORD, PHARMACIE SMITS

since 2020 · until 2026

NICOLE VANSTEENKISTE

Director

Also active at: Pharma Project II

since 2020 · until 2026

Establishments

Establishment units

Physical locations of this company

Registered office

Place Cardinal Mercier 6

1300 Wavre

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.

All companies at this address →

PHARMACIE SMITS ECHT same network

€ 25,036 gross margin · 2025

GS Motorsport Management

Pharma Project II same network

€ 76,950 gross margin · 2025

PHARMACIE SMITS ZONING NORD same network

€ 266,989 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0458.257.001
VAT number: BE 0458.257.001
Registered office: Place Cardinal Mercier 6, 1300 Wavre
Names & denominations: PHARMA PROJECT
Enterprise type: Rechtspersoon
Legal form: Public limited company
Legal situation: Normale toestand
Start date: 19 June 1996
Peppol: Active · Active since 4 May 2026

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMA PROJECT

Warning lights

Financials

What happened to PHARMA PROJECT?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions